Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Mapa de calor
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
X
XBI
State Street SPDR S&P Biotech ETF
136.2
0
USD
+9917.65%
Setor:
Finanças
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+9917.65%
Mudança mensal
+5.17%
Mudança em 6 meses
+11.88%
Mudança anual
+23.67%
Fechamento anterior
1.3
6
Open
136.4
8
Mínimo
136.1
5
High
136.7
3
Volume
649
Mercados
US ETFs
XBI
Abrir gráfico completo
Full chart
Visão geral
Todos os ativos
Mapa de calor
Principais ativos
Market Value
Shares
Weight %
F
FOLD
Amicus Therapeutics Inc
117.0 M
8.2 M
1.5%
PRAX
Praxis Precision Medicines Inc
109.2 M
370.4 K
1.4%
TVTX
Travere Therapeutics Inc
107.7 M
2.8 M
1.4%
BMRN
BioMarin Pharmaceutical Inc
107.2 M
1.8 M
1.4%
HALO
Halozyme Therapeutics Inc
104.1 M
1.5 M
1.3%
ROIV
Roivant Sciences Ltd
103.9 M
4.8 M
1.3%
EXEL
Exelixis Inc
103.4 M
2.4 M
1.3%
REGN
Regeneron Pharmaceuticals Inc
103.0 M
133.4 K
1.3%
PCVX
Vaxcyte Inc
102.8 M
2.2 M
1.3%
MDGL
Madrigal Pharmaceuticals Inc
102.1 M
175.4 K
1.3%
CYTK
Cytokinetics Inc
102.1 M
1.6 M
1.3%
BBIO
Bridgebio Pharma Inc
102.0 M
1.3 M
1.3%
AMGN
Amgen Inc
100.6 M
307.3 K
1.3%
INCY
Incyte Corp
100.6 M
1.0 M
1.3%
KRYS
Krystal Biotech Inc
99.7 M
404.2 K
1.3%
PTCT
PTC Therapeutics Inc
99.3 M
1.3 M
1.3%
RVMD
Revolution Medicines Inc
99.1 M
1.2 M
1.3%
RYTM
Rhythm Pharmaceuticals Inc
99.0 M
925.0 K
1.3%
VRTX
Vertex Pharmaceuticals Inc
98.8 M
217.9 K
1.3%
MRNA
Moderna Inc
98.4 M
3.3 M
1.3%
1
2
3
4
5
6
7
8
Notícias
First Quarter Earnings: Sharpening Sector Divergence
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
3 Reasons To Stick With Growth Stocks In Rotating Markets
Seeking Innovation Beyond Tech? Insight On Healthcare Stocks
Biotech Investors Are Tuning Out the MAHA Chaos
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)
Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA
FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint
Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)
Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird
Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita